Literature DB >> 8897452

P2-purinoceptor antagonists: I. Blockade of P2-purinoceptor subtypes and ecto-nucleotidases by small aromatic isothiocyanato-sulphonates.

R Bültmann1, B Pause, H Wittenburg, G Kurz, K Starke.   

Abstract

Effects of eight small aromatic isothiocyanato-sulphonates, of the aliphatic 2-isothiocyanatoethene-1-sulphonate (IES), and of the parent amines were studied on contractions of the rat vas deferens elicited by alpha, beta-methylene ATP (alpha, beta-MeATP; mediated by P2X-purinoceptors), relaxations of the carbachol-precontracted guinea-pig taenia coli elicited by adenosine 5'-O-(2-thiodiphosphate) (ADP beta S; mediated by P2Y-purinoceptors), and the degradation of ATP by rat vas deferens tissue. The aromatic isothiocyanato-sulphonates all reduced contractions of the rat vas deferens elicited by alpha, beta-methylene ATP. The antagonism was non-competitive, with depression of the maximum of the concentration-response curve of alpha, beta-MeATP and incomplete reversibility. The IC50 values were between 11 and 54 microM. In the guinea pig taenia coli, the aromatic compounds shifted the concentration-response curve of ADP beta S to the right in a surmountable manner (one exception), and where three concentrations were tested, the Arunlakshana-Schild regression was linear and its slope did not differ from 1. The apparent Kd values were between 10 and 214 microM. The removal of ATP from the medium by vas deferens tissue was decreased by the aromatic isothiocyanates with IC25% values between 25 and 464 microM. IES and the parent amines were inactive or almost inactive (parent amines not tested on ATP breakdown). The results indicate that the isothiocyanato residue as well as the aromatic core are essential for P2-purinoceptor blockade. At the P2X-purinoceptor, potency increases with the size of the molecules but is independent of the position of the isothiocyanato and sulphonate substituents. No simple structure-activity relationship for the P2Y-purinoceptor and the ATP-degrading ecto-nucleotidases can be derived beyond the apparent lack of a major influence of the position of the substituents. 2-Isothiocyanatonaphthalene-1-sulphonate (beta-INS) seems to be interesting because of relatively high P2X-selectivity versus both the P2Y-purinoceptor and ecto-nucleotidases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8897452     DOI: 10.1007/bf00168440

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  35 in total

1.  Effects of P2-purinoceptor antagonists on degradation of adenine nucleotides by ecto-nucleotidases in folliculated oocytes of Xenopus laevis.

Authors:  A U Ziganshin; L E Ziganshina; B F King; J Pintor; G Burnstock
Journal:  Biochem Pharmacol       Date:  1996-04-12       Impact factor: 5.858

Review 2.  How should P2X purinoceptors be classified pharmacologically?

Authors:  C Kennedy; P Leff
Journal:  Trends Pharmacol Sci       Date:  1995-05       Impact factor: 14.819

3.  Reactive red 2: a P2y-selective purinoceptor antagonist and an inhibitor of ecto-nucleotidase.

Authors:  R Bültmann; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-11       Impact factor: 3.000

4.  The effects of some possible inhibitors of ectonucleotidases on the breakdown and pharmacological effects of ATP in the guinea-pig urinary bladder.

Authors:  S M Hourani; J A Chown
Journal:  Gen Pharmacol       Date:  1989

5.  Release of ATP in rat vas deferens: origin and role of calcium.

Authors:  A K Kurz; R Bültmann; B Driessen; I von Kügelgen; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-11       Impact factor: 3.000

6.  PPADS selectively antagonizes P2X-purinoceptor-mediated responses in the rabbit urinary bladder.

Authors:  A U Ziganshin; C H Hoyle; X Bo; G Lambrecht; E Mutschler; H G Bäumert; G Burnstock
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

7.  Analgesic activity of anticancer agent suramin.

Authors:  B T Ho; Y Y Huo; J G Lu; R A Newman; V A Levin
Journal:  Anticancer Drugs       Date:  1992-04       Impact factor: 2.248

8.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

9.  Vasoconstrictor and vasodilator responses to various agonists in the rat perfused mesenteric arterial bed: selective inhibition by PPADS of contractions mediated via P2x-purinoceptors.

Authors:  U Windscheif; V Ralevic; H G Bäumert; E Mutschler; G Lambrecht; G Burnstock
Journal:  Br J Pharmacol       Date:  1994-11       Impact factor: 8.739

10.  Antinociceptive effect of intrathecally administered P2-purinoceptor antagonists in rats.

Authors:  B Driessen; W Reimann; N Selve; E Friderichs; R Bültmann
Journal:  Brain Res       Date:  1994-12-15       Impact factor: 3.252

View more
  5 in total

1.  P2-purinoceptor antagonists: II. Blockade of P2-purinoceptor subtypes and ecto-nucleotidases by compounds related to Evans blue and trypan blue.

Authors:  H Wittenburg; R Bültmann; B Pause; C Ganter; G Kurz; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-10       Impact factor: 3.000

2.  P2X1 and P2X3 receptors form stable trimers: a novel structural motif of ligand-gated ion channels.

Authors:  A Nicke; H G Bäumert; J Rettinger; A Eichele; G Lambrecht; E Mutschler; G Schmalzing
Journal:  EMBO J       Date:  1998-06-01       Impact factor: 11.598

3.  P2-purinoceptor antagonists: III. Blockade of P2-purinoceptor subtypes and ecto-nucleotidases by compounds related to suramin.

Authors:  R Bültmann; H Wittenburg; B Pause; G Kurz; P Nickel; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-10       Impact factor: 3.000

4.  Local regulation of [(3)H]-noradrenaline release from the isolated guinea-pig right atrium by P(2X)-receptors located on axon terminals.

Authors:  B Sperlágh; F Erdélyi; G Szabó; E S Vizi
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

5.  Inhibition of Ecto-Apyrase and Ecto-ATPase by Pyridoxal Phosphate-Related Compounds.

Authors:  Carsten Hoffmann; Petra Heine; Gabi Pradel; Yong-Chul Kim; Kenneth A Jacobson; Herbert Zimmermann
Journal:  Drug Dev Res       Date:  2001-01-24       Impact factor: 4.360

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.